FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2051364266> ?p ?o ?g. }

• W2051364266 endingPage "91" @default.
• W2051364266 startingPage "90" @default.
• W2051364266 abstract "Tuberous sclerosis complex (TSC) is an autosomal dominant genetic disorder that occurs in about 1:5,800 individuals (Crino et al., 2006). Approximately two-thirds of cases of TSC are thought to be sporadic, and in families with multiple affected individuals there often is wide phenotypic variability (Lyczkowski et al., 2007). Two genes have been associated with TSC, TSC1 and TSC2, both components of the mammalian target of rapamycin (mTOR) signaling pathway, and a disease-causing mutation can be identified in one of these two genes in 85% of individuals diagnosed with TSC (Crino et al., 2006). Brain involvement occurs in approximately 95% of individuals with TSC; the skin and the brain are the two most frequently affected organs. Neurologic symptoms are common in TSC, as epilepsy occurs in 80–90%, cognitive impairment in 50%, autism spectrum disorders in up to 40% and neurobehavioral disorders in >60% of individuals with TSC. These symptoms are attributable to the neuroanatomic abnormalities seen in TSC, which include cortical tubers, subependymal nodules, and subependymal giant cell tumors. Of the individuals with TSC who develop epilepsy, almost 70% have seizure onset during the first year of life, and approximately one-third of children with TSC will develop infantile spasms. In our center, epilepsy in TSC proved refractory to medical treatment in approximately two-thirds of individuals. The presence of refractory epilepsy and infantile spasms in TSC has been shown to be significantly associated with cognitive impairment, autism spectrum disorders, and psychiatric disorders, including self injurious behaviors (O’Callaghan et al., 2004; Winterkorn et al., 2007; Staley et al., 2008). Infantile spasms occur more commonly in those with TSC2 mutations, consistent with the finding that TSC2 mutations are usually associated with a more severe phenotype than TSC1 mutations (Dabora et al., 2001; Muzykewicz et al., 2009). However, in our TSC center, the prevalence of epilepsy, refractory epilepsy, and epilepsy remission appears similar among those with an identified mutation in TSC1 or TSC2 as well as those with no identified mutation. Antiepileptic drug (AED) therapy remains the first-line treatment of epilepsy in TSC. Because epilepsy in TSC is partial in onset, most available AEDs could be effective. Although there is anecdotal experience on the efficacy of some AEDs, there are no controlled comparison trials with the exception of the treatment of infantile spasms. Vigabatrin has been shown to be superior to other therapies in the treatment of infantile spasms in infants with TSC (Mackay et al., 2004). Dietary therapy as well as vagus nerve stimulation (VNS) are effective in treating epilepsy in TSC (Parain et al., 2001; Kossoff et al., 2005; Major et al., 2008). Epilepsy surgery has also been shown to have an important role in refractory epilepsy in TSC, with several retrospective series showing a significant reduction in seizure activity and often seizure freedom following resection of an identified epileptogenic region (Jarrar et al., 2004; Weiner et al., 2006; Jansen et al., 2007). It is not known if modulators of the mTOR pathway will be effective in treating epilepsy in TSC, and although results in animal models suggest that they may play a role (Zeng et al., 2008), experience with these medications in human epilepsy is limited. The pathophysiology of epilepsy in TSC is not well understood. It is uncertain if cortical tubers, which represent areas of dysgenesis, are themselves epileptogenic, or if instead they are irritating to the neighboring “normal” neurons and thereby lead to epileptogenesis. Recent electrocorticography (ECoG) studies have suggested that the tubers themselves may be electrically “silent,” lending support to the concept that at least in some cases the tubers themselves do not cause epilepsy (Major et al., 2009). It is also unclear if all tubers are “created equal,” or if some are more epileptogenic than others, and if so, why. Most individuals with TSC have multiple tubers involving both hemispheres and all lobes, yet the success of epilepsy surgery in this population argues that not all tubers are associated with epilepsy. Recently, the presence and location of cyst-like tubers have been shown to be associated with epilepsy in TSC, although the pathogenesis and overall significance of these cyst-like changes is unclear (Chu-Shore et al., 2009). In addition, many individuals with TSC and epilepsy have normal brain magnetic resonance imaging (MRI) studies, yet have epilepsy. This further raises the question as to the relationship of cortical tubers and epilepsy in TSC, and suggests that at least in some cases epileptogenicity is instead related to more diffuse and/or subtle cortical or subcortical abnormalities (Tavazoie et al., 2005). It is also unclear if there are factors that put particular individuals with TSC at risk for developing epilepsy, or at particular risk for developing infantile spasms. Possible factors that could influence the development of seizures as well as outcomes in TSC include genotype (TSC1 or TSC2, as well as location and type of mutation), tuber location, tuber burden, and environmental factors. Close surveillance of at-risk populations, for example, infants with multiple cardiac rhabdomyomas, hypopigmented macules, or a family history of TSC, may allow identification of biomarkers suggestive of and perhaps specific for the development of epilepsy in TSC. Such biomarkers could be useful in early identification of those with TSC who are at risk for developing infantile spasms or refractory epilepsy. Our understanding of epilepsy in TSC will hopefully continue to improve, both with a better understanding of the cellular mechanisms involved and characterization of any biomarkers that can be identified. As it does, there will likely be a role for prophylactic treatment of those at high risk. It is uncertain if any of our current treatment options would be ideal in this setting; but many new medications are under development, including both antiepileptic medications as well as modulators of the mTOR pathway. The author has served as a paid consultant for Lundbeck Pharmaceuticals." @default.
• W2051364266 created "2016-06-24" @default.
• W2051364266 creator A5071907476 @default.
• W2051364266 date "2010-01-19" @default.
• W2051364266 modified "2023-09-26" @default.
• W2051364266 title "Managing and understanding epilepsy in tuberous sclerosis complex" @default.
• W2051364266 cites W1580518980 @default.
• W2051364266 cites W1977617725 @default.
• W2051364266 cites W1982574163 @default.
• W2051364266 cites W1990239873 @default.
• W2051364266 cites W1996556344 @default.
• W2051364266 cites W2023938987 @default.
• W2051364266 cites W2028110405 @default.
• W2051364266 cites W2033906796 @default.
• W2051364266 cites W2049318603 @default.
• W2051364266 cites W2066951938 @default.
• W2051364266 cites W2073308168 @default.
• W2051364266 cites W2074133017 @default.
• W2051364266 cites W2080190771 @default.
• W2051364266 cites W2089528225 @default.
• W2051364266 cites W2092491756 @default.
• W2051364266 cites W2109217841 @default.
• W2051364266 cites W2115826968 @default.
• W2051364266 cites W2383259826 @default.
• W2051364266 doi "https://doi.org/10.1111/j.1528-1167.2009.02458.x" @default.
• W2051364266 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/20331728" @default.
• W2051364266 hasPublicationYear "2010" @default.
• W2051364266 type Work @default.
• W2051364266 sameAs 2051364266 @default.
• W2051364266 citedByCount "26" @default.
• W2051364266 countsByYear W20513642662012 @default.
• W2051364266 countsByYear W20513642662013 @default.
• W2051364266 countsByYear W20513642662015 @default.
• W2051364266 countsByYear W20513642662017 @default.
• W2051364266 countsByYear W20513642662018 @default.
• W2051364266 countsByYear W20513642662019 @default.
• W2051364266 countsByYear W20513642662020 @default.
• W2051364266 countsByYear W20513642662021 @default.
• W2051364266 countsByYear W20513642662022 @default.
• W2051364266 countsByYear W20513642662023 @default.
• W2051364266 crossrefType "journal-article" @default.
• W2051364266 hasAuthorship W2051364266A5071907476 @default.
• W2051364266 hasBestOaLocation W20513642661 @default.
• W2051364266 hasConcept C118552586 @default.
• W2051364266 hasConcept C142724271 @default.
• W2051364266 hasConcept C150253156 @default.
• W2051364266 hasConcept C15744967 @default.
• W2051364266 hasConcept C187212893 @default.
• W2051364266 hasConcept C190283241 @default.
• W2051364266 hasConcept C205778803 @default.
• W2051364266 hasConcept C2776194525 @default.
• W2051364266 hasConcept C2776340667 @default.
• W2051364266 hasConcept C2776773979 @default.
• W2051364266 hasConcept C2778186239 @default.
• W2051364266 hasConcept C2778538070 @default.
• W2051364266 hasConcept C2778880634 @default.
• W2051364266 hasConcept C2778980267 @default.
• W2051364266 hasConcept C2779422105 @default.
• W2051364266 hasConcept C502942594 @default.
• W2051364266 hasConcept C54355233 @default.
• W2051364266 hasConcept C71924100 @default.
• W2051364266 hasConcept C86554907 @default.
• W2051364266 hasConcept C86803240 @default.
• W2051364266 hasConceptScore W2051364266C118552586 @default.
• W2051364266 hasConceptScore W2051364266C142724271 @default.
• W2051364266 hasConceptScore W2051364266C150253156 @default.
• W2051364266 hasConceptScore W2051364266C15744967 @default.
• W2051364266 hasConceptScore W2051364266C187212893 @default.
• W2051364266 hasConceptScore W2051364266C190283241 @default.
• W2051364266 hasConceptScore W2051364266C205778803 @default.
• W2051364266 hasConceptScore W2051364266C2776194525 @default.
• W2051364266 hasConceptScore W2051364266C2776340667 @default.
• W2051364266 hasConceptScore W2051364266C2776773979 @default.
• W2051364266 hasConceptScore W2051364266C2778186239 @default.
• W2051364266 hasConceptScore W2051364266C2778538070 @default.
• W2051364266 hasConceptScore W2051364266C2778880634 @default.
• W2051364266 hasConceptScore W2051364266C2778980267 @default.
• W2051364266 hasConceptScore W2051364266C2779422105 @default.
• W2051364266 hasConceptScore W2051364266C502942594 @default.
• W2051364266 hasConceptScore W2051364266C54355233 @default.
• W2051364266 hasConceptScore W2051364266C71924100 @default.
• W2051364266 hasConceptScore W2051364266C86554907 @default.
• W2051364266 hasConceptScore W2051364266C86803240 @default.
• W2051364266 hasIssue "s1" @default.
• W2051364266 hasLocation W20513642661 @default.
• W2051364266 hasLocation W20513642662 @default.
• W2051364266 hasOpenAccess W2051364266 @default.
• W2051364266 hasPrimaryLocation W20513642661 @default.
• W2051364266 hasRelatedWork W156748014 @default.
• W2051364266 hasRelatedWork W1752565791 @default.
• W2051364266 hasRelatedWork W1923381385 @default.
• W2051364266 hasRelatedWork W1933544523 @default.
• W2051364266 hasRelatedWork W198282980 @default.
• W2051364266 hasRelatedWork W2041964064 @default.
• W2051364266 hasRelatedWork W2076268719 @default.
• W2051364266 hasRelatedWork W2153879992 @default.
• W2051364266 hasRelatedWork W2319194829 @default.
• W2051364266 hasRelatedWork W4206413595 @default.

• next